Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
Sumati Gupta(University of Utah), Sunil Sharma(University of Utah), Anupam Verma(Primary Children's Hospital), Mohan R. Kaadige(University of Utah), Timothy L. Mosbruger(Johns Hopkins University), Andrew Butterfield(University of Utah), Kelly Doyle(Intermountain Healthcare), Allison Ast(Primary Children's Hospital), Alexis Weston(Translational Genomics Research Institute)
Cited by 27
Related Papers
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|607
Cellular immune selection with hepatitis C virus persistence in humans
|The Journal of Experimental Medicine|2005|304
The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment
|Immunity|2018|216
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47